N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Status Recruiting

Clinical Trial Summary

This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of Ataxia-Telangiectasia (A-T). There are two phases to this study: the Parent Study, and the Extension Phase. The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the symptomatic treatment of A-T. The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of A-T.

Clinical Trial Description

The primary purpose of the study is to evaluate the safety and efficacy of N-Acetyl-L-Leucine (IB1001) in the treatment of A-T investigating the efficacy in terms of improving symptoms, functioning, and quality of life against the defined endpoints in patients with A-T. Patients will be assessed during three study phases: a baseline period, a 6-week treatment period, and a 6-week post-treatment washout period. If within 6 weeks prior to the initial screening visit, a patient has received any of the prohibited medications defined in the eligibility criteria (irrespective of the preceding treatment duration) a wash-out study-run in of 6 weeks is required prior to the first baseline assessment. All patients will receive the study drug during this study. For each individual patient, the study lasts for approximately 3.5 - 4 months during which there are 6 study visits to the study site. This Extension Phase allows patients who have completed the Parent Study to, at the discretion of the Principal Investigator (PI), continue treatment with N-Acetyl-L-Leucine (IB1001). Patients will receive treatment with IB1001 for two one-year treatment periods, separated by a 6-week washout. All patients will receive the study drug during the treatment period. For each individual patient, the Extension Phase lasts for approximately 25.5 months, during which there are 6 visits to the study site. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03759678
Study type	Interventional
Source	IntraBio Inc
Contact	Michael Strupp, MD
Phone	+44 8081 641283
Email	mstrupp@intrabio.com
Status	Recruiting
Phase	Phase 2
Start date	January 8, 2020
Completion date	March 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Active, not recruiting	`NCT04991701` - A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Active, not recruiting	`NCT05531890` - Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects	Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed	`NCT05252819` - Whole Body MRI for Cancer Surveillance in A-T
Recruiting	`NCT03357978` - Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia	N/A
Withdrawn	`NCT02309632` - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas	N/A
Not yet recruiting	`NCT06324877` - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	N/A
Not yet recruiting	`NCT01075438` - Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients	N/A
Completed	`NCT03962114` - Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	Phase 2
Completed	`NCT04513002` - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis	Phase 2
Completed	`NCT05471310` - Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
Active, not recruiting	`NCT04870866` - NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia	Phase 2
Recruiting	`NCT06193200` - To Evaluate the Effects of EryDex in Patients With A-T	Phase 3
Recruiting	`NCT03563053` - Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study	Phase 3
Recruiting	`NCT05692622` - Home-based Complex Intervention for Children With Ataxia Telangiectasia	N/A
Recruiting	`NCT04037189` - Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Not yet recruiting	`NCT04887311` - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia	Phase 2
Active, not recruiting	`NCT00951886` - The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally	N/A
Recruiting	`NCT01052623` - Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.